APTEVO THERAPEUTICS INC (APVO)

Company Profile

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. The company is headquartered in Seattle, Washington and currently employs 40 full-time employees. The company went IPO on 2016-07-20. The company is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. The company has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and APVO711, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. ALG.APV-527 is a novel investigational bispecific ADAPTIR candidate. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate designed to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.

Company Info

APTEVO THERAPEUTICS INC

2401 4th Ave Ste 1050

Seattle WASHINGTON 98121

P: 12068380500

CEO: Marvin L. White

Employees: 40

Website: http://aptevotherapeutics.com/